Bempedoic acid for polycystic kidney disease
Treatments studied
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if the cholesterol-lowering drug bempedoic acid can slow kidney function loss in people with autosomal dominant polycystic kidney disease (ADPKD). It may offer a new option to protect your kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have autosomal dominant polycystic kidney disease (ADPKD).
- You are between 18 and 60 years old.
- Your kidney function (eGFR) is at least 35 ml/min/1.73m2.
- Your kidney imaging shows moderate to severe cysts (Mayo class 1C-1E or 1B with fast decline).
- You speak English fluently.
- You are not currently taking bempedoic acid, simvastatin over 20 mg, or pravastatin over 40 mg daily.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
This study enrolls adults with autosomal dominant polycystic kidney disease (ADPKD) to better understand the disease and its related changes in the body. It may help researchers find improved ways to track the condition and support future treatments.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
This Phase 2 study tests whether atorvastatin plus an “alkalizing” treatment (sodium bicarbonate) can slow or improve disease effects in people with autosomal dominant polycystic kidney disease (ADPKD). It specifically targets metabolic acidosis (when the body becomes “too acidic”), which may worsen kidney health.
Hear when a new ADPKD (Autosomal Dominant Polycystic Kidney Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.